1. Home
  2. CSWC vs XERS Comparison

CSWC vs XERS Comparison

Compare CSWC & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CSWC
  • XERS
  • Stock Information
  • Founded
  • CSWC 1961
  • XERS 2005
  • Country
  • CSWC United States
  • XERS United States
  • Employees
  • CSWC N/A
  • XERS N/A
  • Industry
  • CSWC Textiles
  • XERS Biotechnology: Pharmaceutical Preparations
  • Sector
  • CSWC Consumer Discretionary
  • XERS Health Care
  • Exchange
  • CSWC Nasdaq
  • XERS Nasdaq
  • Market Cap
  • CSWC 1.1B
  • XERS 1.3B
  • IPO Year
  • CSWC N/A
  • XERS 2018
  • Fundamental
  • Price
  • CSWC $20.82
  • XERS $9.41
  • Analyst Decision
  • CSWC Buy
  • XERS Strong Buy
  • Analyst Count
  • CSWC 5
  • XERS 7
  • Target Price
  • CSWC $23.50
  • XERS $8.00
  • AVG Volume (30 Days)
  • CSWC 656.8K
  • XERS 2.2M
  • Earning Date
  • CSWC 11-03-2025
  • XERS 11-06-2025
  • Dividend Yield
  • CSWC 12.24%
  • XERS N/A
  • EPS Growth
  • CSWC N/A
  • XERS N/A
  • EPS
  • CSWC 1.64
  • XERS N/A
  • Revenue
  • CSWC $209,032,000.00
  • XERS $246,025,000.00
  • Revenue This Year
  • CSWC $14.60
  • XERS $43.89
  • Revenue Next Year
  • CSWC $10.75
  • XERS $20.40
  • P/E Ratio
  • CSWC $12.71
  • XERS N/A
  • Revenue Growth
  • CSWC 10.52
  • XERS 35.62
  • 52 Week Low
  • CSWC $17.46
  • XERS $2.82
  • 52 Week High
  • CSWC $25.80
  • XERS $9.49
  • Technical
  • Relative Strength Index (RSI)
  • CSWC 44.82
  • XERS 67.49
  • Support Level
  • CSWC $20.18
  • XERS $9.11
  • Resistance Level
  • CSWC $21.00
  • XERS $9.49
  • Average True Range (ATR)
  • CSWC 0.35
  • XERS 0.38
  • MACD
  • CSWC 0.12
  • XERS 0.02
  • Stochastic Oscillator
  • CSWC 86.50
  • XERS 91.64

About CSWC Capital Southwest Corporation

Capital Southwest Corp is a U.S.-based investment company that specializes in providing customized financing to middle market companies across various industries. The company's investment objective is to produce attractive risk-adjusted returns by generating current income from debt investments and capital appreciation from equity and equity related investments. It focuses on providing flexible financing solutions through partnerships with business owners, management teams, and financial sponsors. The company's portfolio may include senior debt, second lien, and subordinated debt, preferred stocks, common stocks, and warrants. The primary source company's revenue comprises interest income and dividend income from investments made as well as management fees.

About XERS Xeris Biopharma Holdings Inc.

Xeris Biopharma Holdings Inc is a biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offer Recorlev for the treatment of Cushing's syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis (PPP).

Share on Social Networks: